Literature DB >> 10223912

Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis.

B Phetsuksiri1, A R Baulard, A M Cooper, D E Minnikin, J D Douglas, G S Besra, P J Brennan.   

Abstract

Isoxyl (ISO), a thiourea (thiocarlide; 4, 4'-diisoamyloxythiocarbanilide), demonstrated potent activity against Mycobacterium tuberculosis H37Rv (MIC, 2.5 micrograms/ml), Mycobacterium bovis BCG (MIC, 0.5 microgram/ml), Mycobacterium avium (MIC, 2.0 microgram/ml), and Mycobacterium aurum A+ (MIC, 2.0 microgram/ml), resulting in complete inhibition of mycobacteria grown on solid media. Importantly, a panel of clinical isolates of M. tuberculosis from different geographical areas with various drug resistance patterns were all sensitive to ISO in the range of 1 to 10 microgram/ml. In a murine macrophage model, ISO exhibited bactericidal killing of viable intracellular M. tuberculosis in a dose-dependent manner (0.05 to 2.50 microgram/ml). The selective action of ISO on mycolic acid synthesis was studied through the use of [1, 2-14C]acetate labeling of M. tuberculosis H37Rv, M. bovis BCG, and M. aurum A+. At its MIC for M. tuberculosis, ISO inhibited the synthesis of both fatty acids and mycolic acids (alpha-mycolates by 91.6%, methoxymycolates by 94.3%, and ketomycolates by 91.1%); at its MIC in M. bovis BCG, ISO inhibited the synthesis of alpha-mycolates by 87.2% and that of ketomycolates by 88.5%; and the corresponding inhibitions for M. aurum A+ were 87.1% for alpha-mycolates, 87.2% for ketomycolates, and 86.5% for the wax-ester mycolates. A comparison with isoniazid (INH) and ethionamide (ETH) demonstrated marked similarity in action, i.e., inhibition of the synthesis of all kinds of mycolic acids. However, unlike INH and ETH, ISO also inhibited the synthesis of shorter-chain fatty acids. ISO showed no acute toxicity against primary macrophage cell cultures as demonstrated by diminution of redox activity. A homologous series of ISO derivatives were synthesized. Most derivatives were as effective or more effective than the parent compound in the agar proportion assay. Thus, these thioureas, like INH and ETH, specifically inhibit mycolic acid synthesis and show promise in counteracting a wide variety of drug-sensitive and -resistant strains of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223912      PMCID: PMC89109     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Catalase and peroxidase in mycobacteria. Possible relationship to the mode of action of isoniazid.

Authors:  F WINDER
Journal:  Am Rev Respir Dis       Date:  1960-01

2.  Results of monotherapy with Isoxyl in untreated pulmonary tuberculosis cases of different difficulties and Isoxyl in routine-therapy.

Authors:  F Kampelmann
Journal:  Antibiot Chemother       Date:  1970

3.  Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis.

Authors:  K Mdluli; D R Sherman; M J Hickey; B N Kreiswirth; S Morris; C K Stover; C E Barry
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Authors:  R A Slayden; R E Lee; J W Armour; A M Cooper; I M Orme; P J Brennan; G S Besra
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates.

Authors:  E R Rhoades; I M Orme
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

6.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Relationship between the uptake of isoniazid and its action on in vivo mycolic acid synthesis in Mycobacterium tuberculosis.

Authors:  L Wang; K Takayama
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

8.  Peroxidase-mediated oxidation of isoniazid.

Authors:  H A Shoeb; B U Bowman; A C Ottolenghi; A J Merola
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice.

Authors:  D J Ordway; M G Sonnenberg; S A Donahue; J T Belisle; I M Orme
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

View more
  34 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles.

Authors:  Chenchen Wang; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2010-03-26       Impact factor: 3.246

3.  Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Authors:  Behnoush Hajian; Eric Scocchera; Carolyn Shoen; Jolanta Krucinska; Kishore Viswanathan; Narendran G-Dayanandan; Heidi Erlandsen; Alexavier Estrada; Katarína Mikušová; Jana Korduláková; Michael Cynamon; Dennis Wright
Journal:  Cell Chem Biol       Date:  2019-03-28       Impact factor: 8.116

4.  Galactosyl transferases in mycobacterial cell wall synthesis.

Authors:  Martina Belánová; Petronela Dianisková; Patrick J Brennan; Gladys C Completo; Natisha L Rose; Todd L Lowary; Katarína Mikusová
Journal:  J Bacteriol       Date:  2007-11-30       Impact factor: 3.490

5.  Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.

Authors:  Anna E Grzegorzewicz; Joël Lelièvre; Jorge Esquivias; Bhanupriya Angala; Jiuyu Liu; Richard E Lee; Michael R McNeil; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

6.  Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis.

Authors:  Benjawan Phetsuksiri; Mary Jackson; Hataichanok Scherman; Michael McNeil; Gurdyal S Besra; Alain R Baulard; Richard A Slayden; Andrea E DeBarber; Clifton E Barry; Mark S Baird; Dean C Crick; Patrick J Brennan
Journal:  J Biol Chem       Date:  2003-10-14       Impact factor: 5.157

7.  Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis.

Authors:  Filipa Gil; Anna E Grzegorzewicz; Maria João Catalão; João Vital; Michael R McNeil; Madalena Pimentel
Journal:  Microbiology (Reading)       Date:  2010-01-21       Impact factor: 2.777

8.  A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone.

Authors:  Anna E Grzegorzewicz; Jana Korduláková; Victoria Jones; Sarah E M Born; Juan M Belardinelli; Adrien Vaquié; Vijay A K B Gundi; Jan Madacki; Nawel Slama; Françoise Laval; Julien Vaubourgeix; Rebecca M Crew; Brigitte Gicquel; Mamadou Daffé; Hector R Morbidoni; Patrick J Brennan; Annaik Quémard; Michael R McNeil; Mary Jackson
Journal:  J Biol Chem       Date:  2012-09-21       Impact factor: 5.157

9.  The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds.

Authors:  Simon J Waddell; Richard A Stabler; Ken Laing; Laurent Kremer; Robert C Reynolds; Gurdyal S Besra
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

10.  Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis.

Authors:  Pooja Arora; Aneesh Goyal; Vivek T Natarajan; Eerappa Rajakumara; Priyanka Verma; Radhika Gupta; Malikmohamed Yousuf; Omita A Trivedi; Debasisa Mohanty; Anil Tyagi; Rajan Sankaranarayanan; Rajesh S Gokhale
Journal:  Nat Chem Biol       Date:  2009-02-01       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.